Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Ann Surg Oncol. 2022 Apr;29(4):2673-2680. doi: 10.1245/s10434-021-11009-7. Epub 2021 Nov 23.
To appropriately adopt the organ preservation approach, including subsequent chemoradiotherapy (CRT) in patients who respond to neoadjuvant chemotherapy (NAC), the distribution of residual disease, including pathological lymph nodes (LNs) and recurrence site, needs to be recognized preoperatively. This study was designed to evaluate whether endoscopic response evaluation can predict residual tumor distribution.
Patients with esophageal squamous cell carcinoma who underwent transthoracic esophagectomy (TTE) were retrospectively reviewed. Endoscopic responder (ER) to NAC was defined according to primary tumor endoscopic findings. Recurrence-free survival (RFS), overall survival (OS), and residual tumor patterns were compared between groups.
Of 193 patients, 40 (20%) were classified as ER. ERs showed significantly better RFS and OS. The pN location was found within the primary tumor and cN field in 88% of ERs, which was significantly higher than non-ERs at 63% (p = 0.004). Furthermore, the postoperative recurrence incidence in the distant organ was significantly lower in the ERs than the non-ERs (8%, 32%, respectively, p = 0.002). Residual disease, including postoperative initial recurrence, existed within the same field as the primary tumor and cN in 88% of ERs, significantly higher than 42% in the non-ERs (p < 0.001).
Endoscopic response evaluation can preoperatively predict distribution of residual tumors after NAC, which could help radiation field selection in subsequent definitive CRT when patients prefer to omit TTE. Along with improvements in NAC response rate, this could facilitate organ preservation in patients who respond to NAC.
对于新辅助化疗(NAC)后有反应的患者,包括随后的放化疗(CRT),需要在术前识别器官保存方法,包括残留疾病,包括病理淋巴结(LN)和复发部位。本研究旨在评估内镜反应评估是否可以预测残留肿瘤的分布。
回顾性分析了接受经胸食管切除术(TTE)的食管鳞癌患者。根据原发肿瘤内镜检查结果,将 NAC 内镜反应者(ER)定义为内镜反应者。比较两组之间的无复发生存率(RFS)、总生存率(OS)和残留肿瘤模式。
在 193 例患者中,有 40 例(20%)被归类为 ER。ER 患者的 RFS 和 OS 明显更好。88%的 ER 患者的 pN 位置位于原发肿瘤内和 cN 野内,明显高于非 ER 患者的 63%(p=0.004)。此外,ER 患者的远处器官术后复发率明显低于非 ER 患者(8%、32%,分别为 p=0.002)。88%的 ER 患者的残留疾病,包括术后初始复发,存在于原发肿瘤和 cN 相同的部位,明显高于非 ER 患者的 42%(p<0.001)。
内镜反应评估可在 NAC 后术前预测残留肿瘤的分布,当患者倾向于省略 TTE 时,有助于随后确定 CRT 时的放射野选择。随着 NAC 反应率的提高,这可以促进对 NAC 有反应的患者的器官保存。